查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1841972

全球临床前影像市场：市场规模、份额、趋势分析（按类型、应用、最终用途和地区）、细分市场预测（2025-2033）

Preclinical Imaging Market Size, Share & Trends Analysis Report By Type, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

临床前影像市场摘要

临床前影像市场预计在 2024 年价值 10 亿美元，预计到 2033 年将达到 16 亿美元，2025 年至 2033 年的复合年增长率为 5.6%。这一增长是由慢性病患病率上升、药物开发投资增加以及对非侵入性成像技术的需求增加所推动的。

早期研究中采用先进的成像模式，加上不断扩大的转化研究倡议，进一步推动了市场扩张。政府倡议，例如美国国立卫生研究院 (NIH) 等机构以及欧洲和亚洲类似组织的津贴和资助计划，正在为临床前研究提供大量资金支持。例如，2022 年 9 月，NIH 和 DHHS 发布了一项研究呼吁，针对肠出血性大肠桿菌 (ETEC)、甲型副伤寒沙门氏菌和福氏志贺氏菌进行里程碑主导的临床前疫苗开发。这些津贴用于支持创新疫苗的优化、生产规模扩大、安全性和有效性测试，预计在五年内每年将津贴高达 75 万美元的资金，加速针对不同人群的候选疫苗的开发。符合资格的申请者包括高等教育机构、非营利组织、政府和公司。 NIAID计画向四至六个计划拨款520万美元，用于推动疫苗进入临床前阶段并提交FDA IND申请。新增资金将使研究人员能够购买尖端设备、开发新型成像剂，并进行更全面的临床前研究。资金筹措的增加将直接转化为对临床前影像服务和技术的需求成长，从而推动市场扩张。

临床前影像技术，例如磁振造影(MRI)、电脑断层扫描 (CT)、正子断层扫描 (PET)、单光子发射电脑断层扫描(SPECT) 和超音波，提供了非侵入性方法来可视化和量化动物模型中的细胞和分子层面的生物过程。例如，2025 年 4 月《自然通讯》上的一项关于 i 型树突状细胞 (cDC1s) 免疫疗法的研究使用 PET 成像非侵入性地监测临床前癌症模型中的免疫反应和肿瘤动态。调查团队使用 PET 扫描追踪 cDC1 疫苗接种诱导的组织驻留记忆 T 细胞浸润和活化增加，并将影像讯号与有效的肿瘤控制和復发预防关联起来。

这种影像方法能够即时洞察肿瘤内免疫记忆形成的时空特征，并检验了超越传统检测方法的治疗效果。这项技术对于研究人员在人体临床试验前研究疾病进展、评估新疗法的影响以及优化治疗策略至关重要。

同样，在研究基础设施完善、研发投入充足的已开发国家，这些疾病的高发生率也促使人们高度重视临床前影像技术在治疗开发中的应用，从而促进了市场的成长。此外，慢性病特异性动物模型（例如基因工程小鼠）与成像系统广泛结合使用，这推动了对支援动态成像通讯协定的平台的需求。

阿兹海默症和帕金森氏症等神经退化性疾病也是临床前影像应用的主要驱动力，尤其是在以中枢神经系统为重点的药物研发领域。例如，根据阿兹海默症协会的数据，到2025年，约有720万65岁及以上的美国人将患有阿兹海默症，其中74%的人年龄在75岁及以上。小动物PET、SPECT和MR影像技术对于追踪小鼠模型中的蛋白质聚集、神经发炎和突触活动至关重要。全球失智症负担日益加重，且缺乏根治性治疗方法，这促使使用先进成像技术的早期药物筛检计画激增。

临床前影像正透过人工智慧 (AI) 的应用经历重大变革和改进。 AI 技术处理和分析产生的大量影像数据，使研究人员能够获得关键见解并加速研究进程。例如，2023 年 5 月，荷兰皇家飞利浦公司 (Koninklijke Philips NV) 推出了飞利浦 CT 3500，这是一款创新的高通量 CT 系统，旨在满足大规模筛检专案和常规放射诊断的需求。飞利浦 CT 3500 具有先进的影像重建功能和工作流程改进。这些功能提供了临床医生所需的可靠性、速度和高品质影像，即使在充满挑战的医疗环境中，也能自信地诊断患者并提高操作效率。

然而，动物福利组织的规定对动物试验的限制是阻碍市场成长的一个主要因素。这导致替代方案的采用迅速增加，例如体外测试、微剂量给药、基于电脑的模型、新药虚拟测试以及用于测试的电脑化资料库的开发。然而，使用核磁共振成像 (MRI) 和电脑断层扫描等非侵入性成像技术的手段正在逐渐进入市场。

目录

第一章 分析方法与范围

第二章执行摘要

3. 临床前影像市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 临床前影像市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章临床前影像市场：按类型估计和趋势分析

  • 细分仪表板
  • 全球临床前影像市场：按类型进行的变化分析
  • 全球临床前影像市场规模与趋势分析（按类型）（2021-2033）
  • 情态
    • 光学成像（BLI & F）
    • 磁振造影（MRI）
    • 正子断层扫描（PET）
    • 单光子发射电脑断层扫描（SPECT）
    • 电脑断层扫描（CT）
    • 超音波影像（美国）
    • 光声成像（PAI）
    • 混合成像系统
    • 其他的
  • 试剂
  • 服务

第五章临床前影像市场：按应用的估计和趋势分析

  • 细分仪表板
  • 全球临床前影像市场：按应用进行的变化分析
  • 全球临床前影像市场规模与趋势分析（按应用）（2021-2033）
  • 药物发现与开发
  • 毒理学和药物动力学研究
  • 基础研究、转化研究
  • 疾病机转及病理学研究
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 感染疾病
    • 免疫学和炎症
    • 其他的
  • 生物标记和造影剂的检验
  • 其他的

6. 临床前影像市场：依最终用途的估计和趋势分析

  • 细分仪表板
  • 全球临床前成像市场：按最终用途进行的变化分析
  • 全球临床前影像市场规模和趋势分析（按最终用途）（2021-2033）
  • 製药和生物技术公司
  • CRO（委外研发机构）
  • 学术研究机构
  • 其他的

第七章临床前影像市场：区域估计和趋势分析（按类型、应用和最终用途）

  • 2025年及2033年区域市占率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 市场规模、预测趋势分析，2021-2033年：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 2025年主要企业市占率分析
  • Company Position Analysis
  • 公司分类（新兴企业、创新企业、领导者）
  • 公司简介
    • Cubresa Inc.
    • Bruker Corporation
    • Revvity（PerkinElmer, Inc）
    • FUJIFILM VisualSonics
    • Mediso Ltd.
    • Rigaku（MILabs BV）
    • MR Solutions
    • Aspect Imaging
    • TriFoil Imaging
    • Siemens Healthineers
Product Code: 978-1-68038-881-7

Preclinical Imaging Market Summary

The preclinical imaging market size was estimated at USD 1.0 billion in 2024 and is expected to reach USD 1.6 billion by 2033, growing at a CAGR of 5.6% from 2025 to 2033. This growth is driven by the rising prevalence of chronic diseases, increasing investments in drug development, and growing demand for non-invasive imaging techniques.

The adoption of advanced imaging modalities for early-stage research, coupled with the expansion of translational research initiatives, further accelerates market expansion. Government initiatives, such as grants and funding programs from agencies such as the National Institutes of Health (NIH) in the U.S. and similar organizations in Europe and Asia, are providing substantial financial support for preclinical research. For instance, in September 2022, the NIH and DHHS invited research applications for milestone-driven preclinical vaccine development targeting Enterotoxigenic Escherichia coli (ETEC), Salmonella Paratyphi A, and Shigella species. The funding supported innovative vaccine optimization, production scale-up, safety, and efficacy testing, with up to USD 750,000/year over five years, aiming to accelerate candidate vaccines for diverse populations. Eligible applicants included higher education institutions, nonprofits, governments, and businesses. NIAID planned to award USD 5.2 million for 4-6 projects to advance vaccines through preclinical stages toward FDA IND submission. Such a rise of capital enables researchers to acquire cutting-edge equipment, develop novel imaging agents, and conduct more comprehensive preclinical studies. The increased availability of funding directly translates into a higher demand for preclinical imaging services and technologies, thereby driving market expansion.

Preclinical imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and ultrasound, offer non-invasive methods to visualize and quantify biological processes at the cellular and molecular levels in animal models. For instance, an April 2025 Nature Communications study on type I conventional dendritic cells (cDC1s) immunotherapy used PET imaging to noninvasively monitor immune responses and tumor dynamics in preclinical cancer models. Researchers used PET scans to track the enhanced infiltration and activation of tissue-resident memory T cells induced by cDC1 vaccination, correlating imaging signals with effective tumor control and relapse prevention.

This imaging approach provided real-time insights into the spatial and temporal aspects of immune memory formation within tumors, validating the therapy's efficacy beyond conventional assays. This capability is crucial for researchers to study disease progression, assess the impact of novel therapies, and optimize treatment strategies before clinical trials in humans.

Similarly, the high prevalence of these diseases in developed countries with well established research infrastructures and investment in R&D significantly boosts the focus on preclinical imaging for treatment development, thereby contributing to the market growth. Additionally, chronic disease-specific animal models such as genetically engineered mice are being used extensively in combination with imaging systems, increasing the need for platforms that support dynamic imaging protocols.

Neurodegenerative diseases such as Alzheimer's and Parkinson's are also key drivers for the adoption of preclinical imaging, particularly in CNS-focused drug discovery. For instance, according to the Alzheimer's Association, around 7.2 million Americans aged 65 years and above in the America have Alzheimer's in 2025, with 74% among these being aged of age 75 years or above. Small-animal PET, SPECT, and MR imaging modalities are critical in tracking protein aggregation, neuroinflammation, and synaptic activity in murine models. The rising global burden of dementia and the lack of curative therapies have contributed to the surge in early-stage drug screening programs using advanced imaging techniques.

Preclinical imaging has experienced significant transformation and improvement through the use of AI (Artificial Intelligence). The vast amount of imaging data generated is processed and analyzed with AI techniques, enabling researchers to gain important insights and accelerate their work. For example, in May 2023, Koninklijke Philips N.V. introduced the Philips CT 3500, an innovative high-throughput CT system designed to meet the needs of large-scale screening programs and routine radiology. The Philips CT 3500 features advanced image reconstruction capabilities and workflow improvements. These features provide the reliability, speed, and high-quality imaging needed for clinicians to confidently diagnose patients and enhance operational efficiency, even in challenging medical environments.

On the other hand, the restrictions placed on animal testing due to regulations enforced by organizations that protect animal rights are the major factors impeding the growth of the market. Therefore, the adoption of alternative methods, such as in-vitro tests, micro-dosing, computer-based models, virtual testing of new drugs, and the development of computerized databases for testing purposes, is rapidly increasing. However, modalities with non-invasive imaging techniques such as MRI and CT scans are making their way into the market.

Global Preclinical Imaging Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global preclinical imaging market on the basis of type, application, end use and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Modality
    • Optical Imaging (BLI & F)
    • Magnetic Resonance Imaging (MRI)
    • Positron Emission Tomography (PET)
    • Single Photon Emission Computed Tomography (SPECT)
    • Computed Tomography (CT)
    • Ultrasound Imaging (US)
    • Photoacoustic Imaging (PAI)
    • Hybrid Imaging Systems
    • Bi-Modal
    • SPECT-CT
    • PET-CT
    • SPECT-PET
    • PET-MRI
    • Optical-CT
    • Others
    • Tri-Modal
    • PET-SPECT-CT
    • PET-SPECT-MRI
    • PET-CT-Optical
    • Others
    • Others
  • Reagent
  • Service
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery & Development
  • Toxicology & Pharmacokinetics Studies
  • Basic & Translational Research
  • Disease Mechanism & Pathophysiology Studies
    • Oncology
    • Cardiology
    • Neurology
    • Infectious Diseases
    • Immunology & Inflammation
    • Others
  • Biomarker & Imaging Agent Validation
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharma and Biotech Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Preclinical Imaging Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Preclinical Imaging Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Preclinical Imaging Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Preclinical Imaging Type Market Movement Analysis
  • 4.3. Global Preclinical Imaging Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Modality
    • 4.4.1. Modality market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Optical Imaging (BLI & F)
      • 4.4.2.1. Optical Imaging (BLI & F) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Magnetic Resonance Imaging (MRI)
      • 4.4.3.1. Magnetic Resonance Imaging (MRI) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Positron Emission Tomography (PET)
      • 4.4.4.1. Positron Emission Tomography (PET) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Single Photon Emission Computed Tomography (SPECT)
      • 4.4.5.1. Single Photon Emission Computed Tomography (SPECT) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Computed Tomography (CT)
      • 4.4.6.1. Computed Tomography (CT) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Ultrasound Imaging (US)
      • 4.4.7.1. Ultrasound Imaging (US) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. Photoacoustic Imaging (PAI)
      • 4.4.8.1. Photoacoustic Imaging (PAI) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9. Hybrid Imaging Systems
      • 4.4.9.1. Hybrid Imaging Systems market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2. Bi-Modal
        • 4.4.9.2.1. Bi-Modal market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.2. SPECT-CT
          • 4.4.9.2.2.1. SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.3. PET-CT
          • 4.4.9.2.3.1. PET-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.4. SPECT-PET
          • 4.4.9.2.4.1. SPECT-PET market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.5. PET-MRI
          • 4.4.9.2.5.1. PET-MRI market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.6. Optical-CT
          • 4.4.9.2.6.1. Optical-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.7. Others
          • 4.4.9.2.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.3. Tri-Modal
        • 4.4.9.3.1. Tri-Modal market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.2. PET-SPECT-CT
          • 4.4.9.3.2.1. PET-SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.3. PET-SPECT-MRI
          • 4.4.9.3.3.1. PET-SPECT-MRI market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.4. PET-CT-Optical
          • 4.4.9.3.4.1. PET-CT-Optical market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.5. Others
          • 4.4.9.3.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.10. Others
      • 4.4.10.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Reagent
    • 4.5.1. Reagent market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Service
    • 4.6.1. Service market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Preclinical Imaging Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Preclinical Imaging Application Market Movement Analysis
  • 5.3. Global Preclinical Imaging Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Drug Discovery & Development
    • 5.4.1. Drug Discovery & Development market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Toxicology & Pharmacokinetics Studies
    • 5.5.1. Toxicology & Pharmacokinetics Studies market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Basic & Translational Research
    • 5.6.1. Basic & Translational Research market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Disease Mechanism & Pathophysiology Studies
    • 5.7.1. Disease Mechanism & Pathophysiology Studies market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.2. Oncology
      • 5.7.2.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.3. Cardiology
      • 5.7.3.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.4. Neurology
      • 5.7.4.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.5. Infectious Diseases
      • 5.7.5.1. Infectious Diseases market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.6. Immunology & Inflammation
      • 5.7.6.1. Immunology & Inflammation market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.7. Others
      • 5.7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. Biomarker & Imaging Agent Validation
    • 5.8.1. Biomarker & Imaging Agent Validation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Preclinical Imaging Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Preclinical Imaging End Use Market Movement Analysis
  • 6.3. Global Preclinical Imaging Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Pharma and Biotech Companies
    • 6.4.1. Pharma and biotech companies market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Contract Research Organizations (CROs)
    • 6.5.1. Contract Research Organizations (CROs) market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Academic and Research Institutes
    • 6.6.1. Academic and Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Preclinical Imaging Market: Regional Estimates & Trend Analysis By Type, Application, End Use

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Reimbursement structure
      • 7.5.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement structure
      • 7.5.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement structure
      • 7.5.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Reimbursement structure
      • 7.6.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement structure
      • 7.6.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement structure
      • 7.6.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement structure
      • 7.6.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Reimbursement structure
      • 7.6.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Reimbursement structure
      • 7.6.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Reimbursement structure
      • 7.6.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Competitive scenario
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Reimbursement structure
      • 7.6.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement structure
      • 7.7.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement structure
      • 7.7.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement structure
      • 7.7.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement structure
      • 7.7.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement structure
      • 7.7.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Reimbursement structure
      • 7.7.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Reimbursement structure
      • 7.8.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement structure
      • 7.8.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Competitive scenario
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Reimbursement structure
      • 7.9.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Reimbursement structure
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Competitive scenario
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. Reimbursement structure
      • 7.9.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Competitive scenario
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Reimbursement structure
      • 7.9.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share analysis, 2025
  • 8.4. Company Position Analysis
  • 8.5. Company Categorization (Emerging Players, Innovators and Leaders)
  • 8.6. Company Profiles
    • 8.6.1. Cubresa Inc.
      • 8.6.1.1. Company overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Product benchmarking
      • 8.6.1.4. Strategic initiatives
    • 8.6.2. Bruker Corporation
      • 8.6.2.1. Company overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Product benchmarking
      • 8.6.2.4. Strategic initiatives
    • 8.6.3. Revvity (PerkinElmer, Inc)
      • 8.6.3.1. Company overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Product benchmarking
      • 8.6.3.4. Strategic initiatives
    • 8.6.4. FUJIFILM VisualSonics
      • 8.6.4.1. Company overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Product benchmarking
      • 8.6.4.4. Strategic initiatives
    • 8.6.5. Mediso Ltd.
      • 8.6.5.1. Company overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Product benchmarking
      • 8.6.5.4. Strategic initiatives
    • 8.6.6. Rigaku (MILabs B.V.)
      • 8.6.6.1. Company overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Product benchmarking
      • 8.6.6.4. Strategic initiatives
    • 8.6.7. MR Solutions
      • 8.6.7.1. Company overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Product benchmarking
      • 8.6.7.4. Strategic initiatives
    • 8.6.8. Aspect Imaging
      • 8.6.8.1. Company overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Product benchmarking
      • 8.6.8.4. Strategic initiatives
    • 8.6.9. TriFoil Imaging
      • 8.6.9.1. Company overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Product benchmarking
      • 8.6.9.4. Strategic initiatives
    • 8.6.10. Siemens Healthineers
      • 8.6.10.1. Company overview
      • 8.6.10.2. Financial performance
      • 8.6.10.3. Product benchmarking
      • 8.6.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 3 North America preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 4 North America preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 5 North America preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 7 U.S. preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 8 U.S. preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 9 Canada preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 10 Canada preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 11 Canada preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 13 Mexico preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 14 Mexico preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 15 Europe preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 16 Europe preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 17 Europe preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 18 Europe preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 19 UK preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 20 UK preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 21 UK preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 22 Germany preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 23 Germany preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 24 Germany preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 25 France preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 26 France preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 27 France preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 28 Italy preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 29 Italy preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 30 Italy preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 31 Denmark preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 32 Denmark preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 33 Denmark preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 34 Sweden preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 35 Sweden preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 36 Sweden preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 37 Norway preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 38 Norway preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 39 Norway preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 40 Asia Pacific preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 41 Asia Pacific preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 44 Japan preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 45 Japan preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 46 Japan preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 47 China preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 48 China preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 49 China preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 50 India preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 51 India preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 52 India preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 53 Australia preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 54 Australia preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 55 Australia preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 57 South Korea preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 58 South Korea preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 59 Thailand preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 60 Thailand preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 61 Thailand preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 62 Latin America preclinical imaging market, By Country, 2021 - 2033 (USD Million)
  • Table 63 Latin America preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 64 Latin America preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 65 Latin America preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 66 Brazil preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 67 Brazil preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 68 Brazil preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 69 Argentina preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 70 Argentina preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 71 Argentina preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 72 Middle East & Africa preclinical imaging market, By country, 2021 - 2033 (USD Million)
  • Table 73 Middle East & Africa preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 74 Middle East & Africa preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 75 Middle East & Africa preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 76 South Africa preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 77 South Africa preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 78 South Africa preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 79 Saudi Arabia preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 80 Saudi Arabia preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 81 Saudi Arabia preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 82 UAE preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 83 UAE preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 84 UAE preclinical imaging market, By end use, 2021 - 2033 (USD Million)
  • Table 85 Kuwait preclinical imaging market, By type, 2021 - 2033 (USD Million)
  • Table 86 Kuwait preclinical imaging market, By application, 2021 - 2033 (USD Million)
  • Table 87 Kuwait preclinical imaging market, By end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Preclinical imaging market: Market outlook
  • Fig. 14 Preclinical imaging market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Preclinical imaging market driver impact
  • Fig. 20 Preclinical imaging restraint impact
  • Fig. 21 Preclinical imaging market: type movement analysis
  • Fig. 22 Preclinical imaging market: type outlook and key takeaways
  • Fig. 23 Modality market estimates and forecast, 2021 - 2033
  • Fig. 24 Optical Imaging (BLI & F) market estimates and forecast, 2021 - 2033
  • Fig. 25 MRI market estimates and forecast, 2021 - 2033
  • Fig. 26 PET market estimates and forecast, 2021 - 2033
  • Fig. 27 SPECT market estimates and forecast, 2021 - 2033
  • Fig. 28 CT market estimates and forecast, 2021 - 2033
  • Fig. 29 Ultrasound Imaging (US) market estimates and forecast, 2021 - 2033
  • Fig. 30 Photoacoustic Imaging (PAI) market estimates and forecast, 2021 - 2033
  • Fig. 31 Hybrid Imaging Systems market estimates and forecast, 2021 - 2033
  • Fig. 32 Bi-Modal market estimates and forecast, 2021 - 2033
  • Fig. 33 SPECT-CT market estimates and forecast, 2021 - 2033
  • Fig. 34 PET-CT market estimates and forecast, 2021 - 2033
  • Fig. 35 SPECT-PET market estimates and forecast, 2021 - 2033
  • Fig. 36 PET-MRI market estimates and forecast, 2021 - 2033
  • Fig. 37 Optical-CT market estimates and forecast, 2021 - 2033
  • Fig. 38 Others market estimates and forecast, 2021 - 2033
  • Fig. 39 Tri-Modal market estimates and forecast, 2021 - 2033
  • Fig. 40 PET-SPECT-CT market estimates and forecast, 2021 - 2033
  • Fig. 41 PET-SPECT-MRI market estimates and forecast, 2021 - 2033
  • Fig. 42 PET-CT-Optical market estimates and forecast, 2021 - 2033
  • Fig. 43 Others market estimates and forecast, 2021 - 2033
  • Fig. 44 Reagents market estimates and forecast, 2021 - 2033
  • Fig. 45 Services market estimates and forecast, 2021 - 2033
  • Fig. 46 Preclinical imaging market: application movement analysis
  • Fig. 47 Preclinical imaging market: application outlook and key takeaways
  • Fig. 48 Drug Discovery & Development market estimates and forecast, 2021 - 2033
  • Fig. 49 Toxicology & Pharmacokinetics Studies market estimates and forecast, 2021 - 2033
  • Fig. 50 Basic & Translational Research market estimates and forecast, 2021 - 2033
  • Fig. 51 Disease Mechanism & Pathophysiology Studies market estimates and forecast, 2021 - 2033
  • Fig. 52 Oncology market estimates and forecast, 2021 - 2033
  • Fig. 53 Cardiology market estimates and forecast, 2021 - 2033
  • Fig. 54 Neurology market estimates and forecast, 2021 - 2033
  • Fig. 55 Infectious Diseases market estimates and forecast, 2021 - 2033
  • Fig. 56 Immunology & Inflammation market estimates and forecast, 2021 - 2033
  • Fig. 57 Others market estimates and forecast, 2021 - 2033
  • Fig. 58 Biomarker & Imaging Agent Validation market estimates and forecast, 2021 - 2033
  • Fig. 59 Others market estimates and forecast, 2021 - 2033
  • Fig. 60 Preclinical imaging market: end use movement analysis
  • Fig. 61 Preclinical imaging market: end use outlook and key takeaways
  • Fig. 62 Pharma and biotech companies market estimates and forecast, 2021 - 2033
  • Fig. 63 Contract Research Organizations (CROs) market estimates and forecast, 2021 - 2033
  • Fig. 64 Academic and Research Institutes market estimates and forecast, 2021 - 2033
  • Fig. 65 Others market estimates and forecast, 2021 - 2033
  • Fig. 66 Global Preclinical Imaging Market: regional movement analysis
  • Fig. 67 Global Preclinical Imaging Market: regional outlook and key takeaways
  • Fig. 68 North America
  • Fig. 69 North America market estimates and forecast, 2021 - 2033
  • Fig. 70 U.S.
  • Fig. 71 U.S. market estimates and forecast, 2021 - 2033
  • Fig. 72 Canada
  • Fig. 73 Canada market estimates and forecast, 2021 - 2033
  • Fig. 74 Mexico
  • Fig. 75 Mexico market estimates and forecast, 2021 - 2033
  • Fig. 76 Europe
  • Fig. 77 Europe. market estimates and forecast, 2021 - 2033
  • Fig. 78 UK
  • Fig. 79 UK market estimates and forecast, 2021 - 2033
  • Fig. 80 Germany
  • Fig. 81 Germany market estimates and forecast, 2021 - 2033
  • Fig. 82 France
  • Fig. 83 France market estimates and forecast, 2021 - 2033
  • Fig. 84 Italy
  • Fig. 85 Italy market estimates and forecast, 2021 - 2033
  • Fig. 86 Spain
  • Fig. 87 Spain market estimates and forecast, 2021 - 2033
  • Fig. 88 Denmark
  • Fig. 89 Denmark market estimates and forecast, 2021 - 2033
  • Fig. 90 Sweden
  • Fig. 91 Sweden market estimates and forecast, 2021 - 2033
  • Fig. 92 Norway
  • Fig. 93 Norway market estimates and forecast, 2021 - 2033
  • Fig. 94 Asia Pacific
  • Fig. 95 Asia Pacific market estimates and forecast, 2021 - 2033
  • Fig. 96 Japan
  • Fig. 97 Japan market estimates and forecast, 2021 - 2033
  • Fig. 98 China
  • Fig. 99 China market estimates and forecast, 2021 - 2033
  • Fig. 100 India
  • Fig. 101 India market estimates and forecast, 2021 - 2033
  • Fig. 102 South Korea
  • Fig. 103 South Korea market estimates and forecast, 2021 - 2033
  • Fig. 104 Thailand
  • Fig. 105 Thailand market estimates and forecast, 2021 - 2033
  • Fig. 106 Australia
  • Fig. 107 Australia market estimates and forecast, 2021 - 2033
  • Fig. 108 Latin America
  • Fig. 109 Latin America market estimates and forecast, 2021 - 2033
  • Fig. 110 Brazil
  • Fig. 111 Brazil market estimates and forecast, 2021 - 2033
  • Fig. 112 Argentina
  • Fig. 113 Argentina market estimates and forecast, 2021 - 2033
  • Fig. 114 Middle East and Africa
  • Fig. 115 Middle East and Africa. market estimates and forecast, 2021 - 2033
  • Fig. 116 Saudi Arabia
  • Fig. 117 Saudi Arabia market estimates and forecast, 2021 - 2033
  • Fig. 118 South Africa
  • Fig. 119 South Africa market estimates and forecast, 2021 - 2033
  • Fig. 120 UAE
  • Fig. 121 UAE market estimates and forecast, 2021 - 2033
  • Fig. 122 Kuwait
  • Fig. 123 Kuwait market estimates and forecast, 2021 - 2033
  • Fig. 124 Participant categorization- Preclinical imaging market
  • Fig. 125 Market share of key market players- Preclinical imaging market